In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Pfizer closed at $25.60, slipping 0.43% in the latest session, outperforming broader market losses. While the S&P 500 dropped ...

Sponsored by the Indian Council of Social Science Research (ICSSR), the seminar served as a platform for experts, researchers, and students to discuss the role of artificial intelligence (AI) in ...

The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...